Anavex Life Sciences Corporation chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 0.79
Market capitalization 696.81M
Operating cash flow -27.87M
ESG Scores unknown

Company description

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-09-30 2019-09-30 2020-09-30 2021-09-30
Change To Liabilities 38.23k 683.8k 465.72k 1.19M
Total Cashflows From Investing Activities
Net Borrowings
Total Cash From Financing Activities 8.07M 17.78M 28.35M 153.24M
Change To Operating Activities -884.91k 617.82k -349.2k -1.9M
Issuance Of Stock 8.17M 17.83M 28.75M 158.79M
Net Income -17.25M -26.29M -26.28M -37.91M
Change In Cash -4.51M -745.01k 7.06M 122.86M
Effect Of Exchange Rate
Total Cash From Operating Activities -12.58M -18.53M -21.29M -30.38M
Depreciation
Change To Account Receivables
Other Cashflows From Financing Activities -101.13k -50k -403.76k -5.55M
Change To Netincome 5.52M 6.32M 4.88M 8.23M
Capital Expenditures

Income Statement 2018-09-30 2019-09-30 2020-09-30 2021-09-30
Research Development 11.36M 19.6M 20.62M 28.31M
Income Before Tax -17.18M -26.21M -26.26M -37.64M
Net Income -17.25M -26.29M -26.28M -37.91M
Selling General Administrative 6.14M 7.04M 6.09M 9.15M
Gross Profit
Ebit -17.5M -26.64M -26.71M -37.45M
Operating Income -17.5M -26.64M -26.71M -37.45M
Interest Expense
Income Tax Expense 72.75k 82.18k 22.66k 267.56k
Total Revenue
Cost Of Revenue
Total Other Income ExpenseNet 323.42k 428.46k 455.4k -186.98k
Net Income From Continuing Ops -17.25M -26.29M -26.28M -37.91M
Net Income Applicable To Common Shares -17.25M -26.29M -26.28M -37.91M

Balance Sheet Statement 2018-09-30 2019-09-30 2020-09-30 2021-09-30
Total Liabilities 3.88M 5.04M 7.31M 10.8M
Total Stockholder Equity 22.32M 20.29M 27.24M 150.82M
Other Current Liabilities 443.83k
Total Assets 26.21M 25.33M 34.54M 161.62M
Common Stock 45.94k 52.65k 62.05k 75.92k
Other Current Assets 16.36k
Retained Earnings -107.1M -133.4M -159.68M -197.59M
Treasury Stock
Cash 22.93M 22.19M 29.25M 152.11M
Total Current Liabilities 3.88M 5.04M 7.31M 10.8M
Other Stockholder Equity
Property, Plant, and Equipment
Total Current Assets 26.05M 25.33M 34.54M 161.62M
Net Tangible Assets 22.32M 20.29M 27.24M 150.82M
Net Receivables 1.87M 2.64M 4.85M 9.14M
Accounts Payable 2.96M 3.52M 3.99M 4.74M


Insider Transactions

Here are the insider transactions of stock shares related to Anavex Life Sciences Corporation:

Filer Name Transaction Text Ownership Date Filer Relation Shares
SKARPELOS ATHANASIOSSale at price 9.06 per share.D2022-05-25Director50k
SKARPELOS ATHANASIOSConversion of Exercise of derivative security at price 0.92 per share.D2022-05-25Director50k
MISSLING CHRISTOPHER USale at price 26.00 per share.D2021-06-29Chief Executive Officer51.62k
MISSLING CHRISTOPHER UConversion of Exercise of derivative security at price 1.32 per share.D2021-06-29Chief Executive Officer51.62k
BOENISCH SANDRASale at price 26.53 per share.D2021-06-29Officer and Treasurer166.7k
BOENISCH SANDRAConversion of Exercise of derivative security at price 3.28 - 5.92 per share.D2021-06-29Officer and Treasurer166.7k
FAVUS ELLIOT J. M.D.Sale at price 11.70 per share.D2021-05-21Director145k
FAVUS ELLIOT J. M.D.Conversion of Exercise of derivative security at price 0.92 - 6.11 per share.D2021-05-21Director145k
DONHAUSER PETER D.O.Purchase at price 10.93 per share.D2021-05-17Director1k
FAVUS ELLIOT J. M.D.Sale at price 12.66 per share.D2021-02-24Director145.5k
FAVUS ELLIOT J. M.D.Conversion of Exercise of derivative security at price 2.58 - 3.28 per share.D2021-02-24Director145.5k
DONHAUSER PETER D.O.Purchase at price 12.62 - 12.97 per share.D2021-02-19Director1.17k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Anavex Life Sciences Corporation. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Anavex Life Sciences Corporation

Here is the result of two systematic investment strategies applied to Anavex Life Sciences Corporation. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Anavex Life Sciences Corporation

The following chart shows the equity curve of the two systematic investment strategies applied to Anavex Life Sciences Corporation:

Anavex Life Sciences Corporation automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 633.6% on the backtest period.

Performance at glance

Performance

633.6 %

Latent gain

11084.54 $

Invested capital

1749.46 $

Annualized return

154.54 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Anavex Life Sciences Corporation

This is the result of two momentum investment strategies applied to Anavex Life Sciences Corporation. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Anavex Life Sciences Corporation

The following chart shows all the entries opened by the momentum investment system on Anavex Life Sciences Corporation:

Anavex Life Sciences Corporation momentum entries
  • The first momentum investment strategy would give 664.73% of return on Anavex Life Sciences Corporation. That represents 33207.38$ of latent gain with 4995.62$ of employed capital.
  • The second momentum investment strategy would give 560.44% of return on Anavex Life Sciences Corporation. That represents 22288.94$ of latent gain with 3977.06$ of employed capital.
Performance at glance (1Q Momentum)

Performance

664.73 %

Latent gain

33207.38 $

Invested capital

4995.62 $

Annualized return

307.54 %
Performance at glance (2Q Momentum)

Performance

560.44 %

Latent gain

22288.94 $

Invested capital

3977.06 $

Annualized return

154.82 %

Momentum equity curve on Anavex Life Sciences Corporation

The following chart shows the equity curve of the two momentum strategies applied to Anavex Life Sciences Corporation:

Anavex Life Sciences Corporation momentum equity

Note: the dividends potentially given by Anavex Life Sciences Corporation are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Anavex Life Sciences Corporation

The following chart shows the employed capital evolution of the two momentum strategies on Anavex Life Sciences Corporation since the beginning:

Anavex Life Sciences Corporation

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Anavex Life Sciences Corporation

Buy the dip entry openings on Anavex Life Sciences Corporation

Anavex Life Sciences Corporation

The performance achieved by the robo-advisor on Anavex Life Sciences Corporation is 645.83%. That represents 6452.84$ of latent gain with 999.16$ of employed capital. The following chart shows Anavex Life Sciences Corporation stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Anavex Life Sciences Corporation, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

645.83 %

Latent gain

6452.84 $

Invested capital

999.16 $

Annualized return

307.54 %

Equity curve of the strategy applied to Anavex Life Sciences Corporation

The following chart shows the result of the investment strategy applied to Anavex Life Sciences Corporation:

Anavex Life Sciences Corporation

Note: the dividends potentially given by Anavex Life Sciences Corporation are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Anavex Life Sciences Corporation

The following chart shows the employed capital evolution since the beginning of the investment strategy on Anavex Life Sciences Corporation:

Anavex Life Sciences Corporation

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Anavex Life Sciences Corporation

In this section, I will compare the three previous investment strategies applied to Anavex Life Sciences Corporation.

Equity curve comparison on Anavex Life Sciences Corporation

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Anavex Life Sciences Corporation investment strategy comparison

Employed capital comparison on Anavex Life Sciences Corporation

Anavex Life Sciences Corporation investment comparison

Performance comparison on Anavex Life Sciences Corporation

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 633.6% 11084.54$ 1749.46$ 154.54%
Momentum 1 quarter 664.73% 33207.38$ 4995.62$ 172.21%
Momentum 2 quarters 560.44% 22288.94$ 3977.06$ 154.82%
Non-directional 645.83% 6452.84$ 999.16$ 307.54%
Annualized return comparison

Automatic investment

154.54 %

Momentum 1Q

154.82 %

Momentum 2Q

154.82 %

Non-directional

307.54 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Anavex Life Sciences Corporation:

Positive correlations

Most correlated stocks this year

  • Anavex Life Sciences Corporation

  • Most correlated stocks last 3 months

  • Heico Corp - Class A
  • Novartis AG
  • Anavex Life Sciences Corporation
  • HONG LEONG FIN
  • ASCOTT TRUST

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • UMP

  • Note: The algorithm computes the probability of correlation between Anavex Life Sciences Corporation and the other stocks. There may be false positives or some missing correlated stocks. If the price of Anavex Life Sciences Corporation does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Anavex Life Sciences Corporation
    Country United States
    City New York
    Address 51 West 52nd Street
    Phone 844 689 3939
    Website www.anavex.com
    FullTime employees 25
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker AVXL
    Market www.nasdaq.com

    Anavex Life Sciences Corporation ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown